| Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab (NCT07061080) | Grupo Espanol de Tumores Neuroendocrinos | 2025-12-18 |
| Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (NCT06878664) | Grupo Espanol de Tumores Neuroendocrinos | 2025-06-12 |
| Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion in Spain (SPAINTRK) (NCT06837090) | Grupo Espanol de Tumores Neuroendocrinos | 2025-02-11 |
| Sacituzumab govitEcan in THYroid Cancers (NCT06235216) | Grupo Espanol de Tumores Neuroendocrinos | 2024-09-13 |
| Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. (NCT05918302) | Grupo Espanol de Tumores Neuroendocrinos | 2023-10-27 |
| Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. (NCT05660954) | Grupo Espanol de Tumores Neuroendocrinos | 2023-05-25 |
| Nutrition in Gastroenteropancreatic Neuroendocrine Tumor (NCT04986085) | Grupo Espanol de Tumores Neuroendocrinos | 2021-02-24 |
| Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (NCT04400474) | Grupo Espanol de Tumores Neuroendocrinos | 2020-10-07 |
| Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. (NCT03980925) | Grupo Espanol de Tumores Neuroendocrinos | 2019-10-11 |
| GETNE Registration of Thyroid Cancer (NCT03765333) | Grupo Espanol de Tumores Neuroendocrinos | 2019-05-28 |
| Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (NCT03753919) | Grupo Espanol de Tumores Neuroendocrinos | 2019-04-02 |
| Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (NCT03095274) | Grupo Espanol de Tumores Neuroendocrinos | 2017-04-11 |
| Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib (NCT02713763) | Grupo Espanol de Tumores Neuroendocrinos | 2017-02-14 |
| Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors (NCT02678780) | Grupo Espanol de Tumores Neuroendocrinos | 2015-10-01 |
| Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria (NCT02841865) | Grupo Espanol de Tumores Neuroendocrinos | 2015-07-24 |
| A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours (NCT02402062) | Grupo Espanol de Tumores Neuroendocrinos | 2015-05-11 |
| A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) (NCT02806648) | Grupo Espanol de Tumores Neuroendocrinos | 2015-05-01 |
| Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor (NCT02246127) | Grupo Espanol de Tumores Neuroendocrinos | 2014-10-27 |
| Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas (NCT01744249) | Grupo Espanol de Tumores Neuroendocrinos | 2011-11-01 |
| Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET (NCT01567488) | Grupo Espanol de Tumores Neuroendocrinos | 2011-06-08 |
| Pazopanib as Single Agent in Advanced NETs (NCT01280201) | Grupo Espanol de Tumores Neuroendocrinos | 2011-01-26 |